Novartis wins rare cancer pediatric indication, BMS layoffs, McKinsey under fire [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — Novartis wins rare cancer pediatric indication for Lutathera
The bad — BMS unveils cost-saving initiative, layoffs
The ugly — McKinsey under fire for alleged role in opioid crisis